Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.64 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.55 |
| ▸ | IGF1R | P08069 | 5/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | LYN | P07948 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988127 | 0.92 | RIPK1 (0.65) | AAK1RIPK1IGF1RSTING1IKBKB | |
| SCHEMBL22049648 | 0.91 | AAK1 (0.58) | AAK1RIPK1IGF1RSTING1TRPV1 | |
| SCHEMBL22049644 | 0.90 | AAK1 (0.68) | AAK1RIPK1IGF1RSTING1BRAF | |
| SCHEMBL22049501 | 0.89 | AAK1 (0.61) | AAK1RIPK1IGF1RSTING1IKBKB | |
| SCHEMBL22049567 | 0.89 | AAK1 (0.59) | AAK1RIPK1IGF1RSTING1IKBKB | |
| SCHEMBL22050319 | 0.88 | AAK1 (0.61) | AAK1RIPK1IGF1RSTING1TRPV1 | |
| SCHEMBL22050275 | 0.88 | AAK1 (0.56) | AAK1RIPK1IGF1RSTING1IKBKB | |
| SCHEMBL22049421 | 0.86 | CA12 (0.58) | AAK1RIPK1IGF1RSTING1IKBKB | |
| SCHEMBL22049601 | 0.86 | AAK1 (0.58) | AAK1RIPK1IGF1RSTING1TRPV1 | |
| SCHEMBL21988041 | 0.84 | STING1 (0.59) | AAK1RIPK1IGF1RSTING1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | AAK1 1490/4885RIPK1 195/4885IGF1R 2592/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | AAK1 1803/4885RIPK1 245/4885IGF1R 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.